Olopatadine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Olopatadine
Olopatadine.svg
Systematic (IUPAC) name
{(11Z)-11-[3-(dimethylamino)propylidene]-6,11-
dihydrodibenzo[b,e]oxepin-2-yl}acetic acid
Clinical data
Trade names Patanol and others
AHFS/Drugs.com monograph
MedlinePlus a602025
Pregnancy cat.
  • C
Legal status
?
Routes Ophthalmic, intranasal, oral
Pharmacokinetic data
Half-life 3 hours
Identifiers
CAS number 113806-05-6 YesY
ATC code S01GX09 R01AC08
PubChem CID 5281071
DrugBank DB00768
ChemSpider 4444528 YesY
UNII D27V6190PM YesY
KEGG D08293 YesY
ChEMBL CHEMBL1189432 N
Chemical data
Formula C21H23NO3 
Mol. mass 337.412 g/mol
 N (what is this?)  (verify)

Olopatadine hydrochloride is an antihistamine (as well as anticholinergic and mast cell stabilizer), sold as a prescription eye drop (0.2% solution, Pataday (or Patanol S in some countries), manufactured by Alcon). It is used to treat itching associated with allergic conjunctivitis (eye allergies). Olopatadine hydrochloride 0.1% is sold as Patanol (or Opatanol in some countries). A decongestant nasal spray formulation is sold as Patanase, which was approved by the FDA on April 15, 2008.[1] It is also available as an oral tablet in Japan under the tradename Allelock, manufactured by Kyowa Hakko Kogyo.[2]

It should not be used to treat irritation caused by contact lenses. The usual dose for Patanol is 1 drop in each affected eye 2 times per day, with 6 to 8 hours between doses.

There is potential for Olopatadine as a treatment modality for steroid rebound (red skin syndrome.) [3]

Olopatadine was developed by Kyowa Hakko Kogyo.[4]

Side Effects[edit]

Some known side effects include headache (7% of occurrence), eye burning and/or stinging (5%), blurred vision, dry eyes, foreign body sensation, hyperemia, keratitis, eyelid edema, pruritus, asthenia, sore throat (pharyngitis), rhinitis, sinusitis, and taste perversion.

Synthesis[edit]

Olopatadine synthesis:[5]

See also[edit]

References[edit]

  1. ^ Drugs.com, Alcon's Patanase Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms
  2. ^ Kyowa Hakko Kogyo Co., Ltd. (2007). "ALLELOCK Tablets 2.5 & ALLELOCK Tablets 5 (English)" (PDF). Retrieved 2008-08-10. 
  3. ^ Tamura T, Matsubara M, Hasegawa K, Ohmori K, Karasawa A. (2005). "Olopatadine hydrochloride suppresses the rebound phenomenon after discontinuation of treatment with a topical steroid in mice with chronic contact hypersensitivity.". 
  4. ^ Kyowa Hakko Kogyo Co., Ltd. (2002). "Company History". Company Information. Kyowa Hakko Kogyo Co., Ltd. Retrieved 16 September 2010. 
  5. ^ Ueno, K.; Kubo, S.; Tagawa, H.; Yoshioka, T.; Tsukada, W.; Tsubokawa, M.; Kojima, H.; Kasahara, A. (1976). "6,11-Dihydro-11-oxodibenz[b,e]oxepinacetic acids with potent antiinflammatory activity". Journal of Medicinal Chemistry 19 (7): 941. doi:10.1021/jm00229a017.  edit

External links[edit]